Poziotinib in Previously Treated Patients With NSCLC and HER2 Exon 20 Insertion Mutations
Last Updated: Monday, December 20, 2021
In a cohort of the phase II ZENITH20-2 trial reported in the Journal of Clinical Oncology, Le et al found that the tyrosine kinase inhibitor poziotinib produced responses in previously treated patients with non–small cell lung cancer and HER2 exon 20 insertion mutations.
Advertisement
News & Literature Highlights